ClinicalTrials.gg
CompletedNCT00643851Updated Jan 30, 2023Results posted

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

A Phase 3 interventional study of Dapagliflozin and Metformin XR in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 99 sites in 7 countries. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
994
Allocation
Randomized
Ages
18 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
14th of 180
994 · median 82
Started
2008
with 7 others
Phase 3
47 of 180
4 open now
Registered
9th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 8 that started in 2008, is one of 47 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes, when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety of this treatment will also be studied

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males \& females, 18-77 years old inclusive, with type 2 diabetes and with inadequate glycemic control
  • Drug naive or treated with anti-diabetic medication for \< 24 weeks since original diagnosis
  • C-peptide ≥ 1.0 ng/mL
  • ≤ 45.0 kg/m
  • Serum creatinine \< 1.50 mg/dL for men or \< 1.40 mg/dL for women

Exclusion criteria

Exclusion Criteria:

  • and/or ALT >3.0 times the (ULN)
  • Serum total > 2.0 mg/dL
  • Creatine kinase > 3X the upper limit of normal (ULN)
  • Symptoms of severely uncontrolled diabetes
  • Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric or rheumatic diseases
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
994 participants (actual)

Study arms

  • Experimental
    Arm 1

    Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)

    Drug: Dapagliflozin · Drug: Metformin XR

  • Experimental
    Arm 2

    Dapagliflozin (5 mg)

    Drug: Dapagliflozin

  • Active comparator
    Arm 3

    Metformin XR (500 mg up to 2000 mg)

    Drug: Metformin XR

Interventions

  • Tablets, Oral, Once daily, 24 weeks

    Also known as: BMS-512148

  • Tablets, Oral, Once daily, 24 weeks

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])

    HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double- blind period.

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the double-blind period.

    Time frame: From Baseline to Week 24

  2. Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Mean and standard error for percentage of participants estimated by modified logistic regression model.

    Time frame: From Baseline to Week 24

  3. Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) in Subjects With Baseline HbA1c ≥ 9% at Week 24 (Last Observation Carried Forward [LOCF])

    HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.

    Time frame: From Baseline to Week 24

  4. Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.

    Time frame: From Baseline to Week 24

  5. Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.

    Time frame: From Baseline to Week 24

07

Results

Posted Feb 23, 2017

Participant flow

Of 994 participants enrolled, 632 completed a qualification period. Of these 632 participants, 603 were randomized. Of these 603 randomized, 598 received at least one dose of study medication treatment. Of these 598 randomized, 518 completed double-blind treatment period.

Participant flow — Overall Study
MilestoneDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
Started194203201
Completed177170171
Not completed173330
Withdrew: Death010
Withdrew: Lack of efficacy010
Withdrew: Adverse event266
Withdrew: Lost to follow-up469
Withdrew: Withdrawal by subject8159
Withdrew: Non-compl., not met criteria, etc.346

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])

HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double- blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · % of hemoglobin
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
% of hemoglobinDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])-2.05 ± 0.0892-1.19 ± 0.0866-1.35 ± 0.0868
Statistical analysis
  • Dapagliflozin 5 mg + Metformin XR vs Dapagliflozin 5 mg · ANCOVA · p = <0.0001 (Primary endpoint was tested at alpha=0.05; significance was claimed only if DAPA 5MG + MET was superior to both controls.) · Mean difference (final values): -0.86 · 95% CI -1.11 to -0.62
  • Dapagliflozin 5 mg + Metformin XR vs Metformin XR · ANCOVA · p = <0.0001 (Primary endpoint was tested at alpha=0.05; significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): -0.70 · 95% CI -0.94 to -0.45
SecondaryAdjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · mg/dL
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])
mg/dLDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])-61.0 ± 2.783-42.0 ± 2.708-33.6 ± 2.728
Statistical analysis
  • Dapagliflozin 5 mg + Metformin XR vs Dapagliflozin 5 mg · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): -19.1 · 95% CI -26.7 to -11.4
  • Dapagliflozin 5 mg + Metformin XR vs Metformin XR · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): -27.5 · 95% CI -35.1 to -19.8
SecondaryPercentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Mean and standard error for percentage of participants estimated by modified logistic regression model.

Time frame:
From Baseline to Week 24
Reported as:
Mean · Percentage of participants
Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])
Percentage of participantsDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])52.4 ± 3.58122.5 ± 2.74134.6 ± 3.296
Statistical analysis
  • Dapagliflozin 5 mg + Metformin XR vs Dapagliflozin 5 mg · modified logistic regression · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): 29.9 · 95% CI 20.8 to 39.0
  • Dapagliflozin 5 mg + Metformin XR vs Metformin XR · ANCOVA · p = 0.0003 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): 17.8 · 95% CI 8.1 to 27.4
SecondaryAdjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) in Subjects With Baseline HbA1c ≥ 9% at Week 24 (Last Observation Carried Forward [LOCF])

HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · % of hemoglobin
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) in Subjects With Baseline HbA1c ≥ 9% at Week 24 (Last Observation Carried Forward [LOCF])
% of hemoglobinDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) in Subjects With Baseline HbA1c ≥ 9% at Week 24 (Last Observation Carried Forward [LOCF])-3.01 ± 0.1381-1.67 ± 0.1361-1.82 ± 0.1320
Statistical analysis
  • Dapagliflozin 5 mg + Metformin XR vs Dapagliflozin 5 mg · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): -1.34 · 95% CI -1.72 to -0.96
  • Dapagliflozin 5 mg + Metformin XR vs Metformin XR · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): -1.19 · 95% CI -1.57 to -0.82
SecondaryAdjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · kg
Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])
kgDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])-2.66 ± 0.2428-2.61 ± 0.2361-1.29 ± 0.2378
Statistical analysis
  • Dapagliflozin 5 mg + Metformin XR vs Dapagliflozin 5 mg · ANCOVA · p = 0.8769 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): -0.05 · 95% CI -0.72 to 0.61
  • Dapagliflozin 5 mg + Metformin XR vs Metformin XR · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.) · Mean difference (final values): -1.37 · 95% CI -2.04 to -0.71
SecondaryAdjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · kg
Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])
kgDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])-3.04 ± 0.3031-2.88 ± 0.2890-1.47 ± 0.2907
Statistical analysis
  • Dapagliflozin 5 mg + Metformin XR vs Dapagliflozin 5 mg · ANCOVA · Mean difference (final values): -0.16 · 95% CI -0.98 to 0.66
  • Dapagliflozin 5 mg + Metformin XR vs Metformin XR · ANCOVA · Mean difference (final values): -1.57 · 95% CI -2.40 to -0.74

Adverse events

Collected over Onset on or after the first date of double-blind treatment and on or prior to the last day of double-blind treatment 24 weeks plus 4 days for non-serious adverse event; plus 30 days for serious adverse event.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 5 mg + Metformin XR—6/194 (3.1%)48/194 (24.7%)
Dapagliflozin 5 mg—9/203 (4.4%)32/203 (15.8%)
Metformin XR—7/201 (3.5%)40/201 (19.9%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
PULMONARY TUBERCULOSISInfections and infestations3/1941/2031/201
DIABETES MELLITUSMetabolism and nutrition disorders0/1942/2030/201
HERPES ZOSTERInfections and infestations1/1940/2030/201
PNEUMONIAInfections and infestations1/1940/2030/201
OESOPHAGITISGastrointestinal disorders1/1940/2030/201
GUN SHOT WOUNDInjury, poisoning and procedural complications1/1940/2030/201
CELLULITISInfections and infestations0/1941/2031/201
CYSTITISInfections and infestations0/1940/2031/201
PYELONEPHRITISInfections and infestations0/1940/2031/201
GASTROINTESTINAL OBSTRUCTIONGastrointestinal disorders0/1940/2031/201
Most frequent other events
Most frequent other events
EventDapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XR
DIARRHOEAGastrointestinal disorders15/1948/20314/201
NAUSEAGastrointestinal disorders11/1944/2038/201
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations10/19410/20311/201
DYSLIPIDAEMIAMetabolism and nutrition disorders9/19411/2038/201
URINARY TRACT INFECTIONInfections and infestations10/1949/20310/201

Baseline characteristics

All randomized participants who received at least 1 dose of study medication

Age, Continuous
Age, Continuous(Years)Dapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XRTotal
Mean51.7 ± 9.3152.3 ± 10.2051.8 ± 9.8052.0 ± 9.77
Age, Customized
Age, Customized(Participants)Dapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XRTotal
Younger than 65 years177183184544
65 to younger than 75 years17171650
75 years and older0314
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Dapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XRTotal
Male789295265
Female116111106333
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapagliflozin 5 mg + Metformin XRDapagliflozin 5 mgMetformin XRTotal
White153166158477
Black/African American84618
Asian323335100
Other1023
08

Study locations

99 sites
  • Greystone Medical Research, Llc
    Birmingham, Alabama 35242, United States
  • Winston Technology Research, Llc
    Haleyville, Alabama 35565, United States
  • Clinical Research Advantage, Inc.
    Tempe, Arizona 85282, United States
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Southland Clinical Research Center, Inc.
    Fountain Valley, California 92708, United States
  • Valley Research
    Fresno, California 93720, United States
  • Central Florida Clinical Trials, Inc.
    Altamonte Springs, Florida 32701, United States
  • Clinical Therapeutics Corporation
    Coral Gables, Florida 33134, United States
  • Florida Research Network, Llc
    Gainesville, Florida 32605, United States
  • Fpa Clinical Research
    Kissimmee, Florida 34741, United States
  • Nextphase Clinical Trials, Inc.
    Miami, Florida 33145, United States
  • Middle Georgia Drug Study Center, Llc
    Perry, Georgia 31069, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Jackson Clinic
    Rolling Fork, Mississippi 39159, United States
  • Mercy Medical Group/Dba Woodlake Research
    Chesterfield, Missouri 63017, United States
  • Hudson Valley Clinical Research Center
    Kingston, New York 12401, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Crescent Medical Research
    Salisbury, North Carolina 28144, United States
  • Community Health Care, Inc.
    Canal Fulton, Ohio 44614, United States
  • Wells Institute For Health Awareness
    Kettering, Ohio 45429, United States
  • Newark Physician Associates
    Newark, Ohio 43055, United States
  • Physician Research, Inc.
    Zanesville, Ohio 43701, United States
  • Gilbert Medical Research, Llc
    Bethany, Oklahoma 73008, United States
  • Integris Family Care South Penn
    Oklahoma City, Oklahoma 73159, United States
  • Integris Family Care Yukon
    Yukon, Oklahoma 73099, United States
  • Willamette Valley Clinical Studies
    Eugene, Oregon 97404, United States
  • Commonwealth Primary Care, Pc / Fleetwood Clinical Research
    Fleetwood, Pennsylvania 19522, United States
  • Biomedical Research Associates, Llc
    Shippensburg, Pennsylvania 17257, United States
  • Safe Harbor Clinical Research
    East Providence, Rhode Island 02914, United States
  • Southeastern Research Associates, Inc.
    Greenville, South Carolina 29605, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Middle Tennessee Clinical Research
    Fayetteville, Tennessee 37334, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Endocrine Associates
    Houston, Texas 77004, United States
  • Village Family Practice
    Houston, Texas 77024, United States
  • Non-Invasive Cardiovascular, Pa
    Houston, Texas 77074, United States
  • Excel Clinical Research, Llc
    Houston, Texas 77081, United States
  • Texas Center For Drug Development
    Houston, Texas 77081, United States
  • Inst. Of Clin. Research At The Diabetes Cntr. Of The Sw
    Midland, Texas 79705, United States
  • Hill Country Medical Associates
    New Braunfels, Texas 78130, United States
  • Southwest Clinical Research Center, Llc
    Pearland, Texas 77584, United States
  • Covenant Clinical Research, Pa
    San Antonio, Texas 78229, United States
  • S.A.M. Clinical Research Center
    San Antonio, Texas 78229, United States
  • Local Institution
    Guri-Si, Gyeonggi-Do 471-701, Korea, Republic of
  • Local Institution
    Seoul, Nowon-Gu 471-701, Korea, Republic of
  • Local Institution
    Bucheon, 420-717, Korea, Republic of
  • Local Institution
    Incheon, 105-760, Korea, Republic of
  • Local Institution
    Incheon, 400-711, Korea, Republic of
  • Local Institution
    Seoul, 137-040, Korea, Republic of
  • Local Institution
    Sungnam-Si, Gyeonggi-Do, 463-070, Korea, Republic of
  • Local Institution
    Ciudad De Mexico, Distrito Federal 14000, Mexico
  • Local Institution
    Pachuca, Hidelgo 42090, Mexico
  • Local Institution
    Guadalajara, Jalisco 44100, Mexico
  • Local Institution
    Guadalajara, Jalisco 44650, Mexico
  • Local Institution
    Guadalajara, Jalisco 44670, Mexico
  • Local Institution
    Morelia, Michioacan 58070, Mexico
  • Local Institution
    Monterrey, Nl, Nuevo Leon 64400, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64000, Mexico
  • Local Institution
    Tampico, Tamaulipas 89000, Mexico
  • Local Institution
    Merida, Yucatan 97070, Mexico
  • Local Institution
    Aguascalientes, 20127, Mexico
  • Local Institution
    Durango, 34000, Mexico
  • Local Institution
    Veracruz, 91910, Mexico
  • Local Institution
    Cebu City, 6000, Philippines
  • Local Institution
    Jaro Iloilo City, 5000, Philippines
  • Local Institution
    Las Pinas City, 1740, Philippines
  • Local Institution
    Marikina City, 1800, Philippines
  • Local Institution
    Pasig City, 1600, Philippines
  • Local Institution
    Quezon City, 1100, Philippines
  • Local Institution
    Ponce, 00716, Puerto Rico
  • Local Institution
    Ponce, 00717, Puerto Rico
  • Local Institution
    San Juan, 00920, Puerto Rico
  • Local Institution
    San Juan, 00926, Puerto Rico
  • Local Institution
    Villa Fontana, 00983, Puerto Rico
  • Local Institution
    Arkhangelsk, 163045, Russian Federation
  • Local Institution
    Dzerzhinskiy, 140091, Russian Federation
  • Local Institution
    Kemerovo, 650066, Russian Federation
  • Local Institution
    Moscov, 119048, Russian Federation
  • Local Institution
    Moscow, 125299, Russian Federation
  • Local Institution
    Nizhniy Novgorod, 603018, Russian Federation
  • Local Institution
    Novosibirsk, 630091, Russian Federation
  • Local Institution
    Novosibirsk, 630117, Russian Federation
  • Local Institution
    Saint-Petersburg, 190068, Russian Federation
  • Local Institution
    Saratov, 410028, Russian Federation
  • Local Institution
    St. Petersburg, 191015, Russian Federation
  • Local Institution
    Volgograd, 400001, Russian Federation
  • Local Institution
    Voronezh, 394018, Russian Federation
  • Local Institution
    Yaroslav, 150003, Russian Federation
  • Local Institution
    Dnepropetrovsk, 49023, Ukraine
  • Local Institution
    Donetsk, 83003, Ukraine
  • Local Institution
    Kiev, 04050, Ukraine
  • Local Institution
    Kiev, 4114, Ukraine
  • Local Institution
    Lviv, 79010, Ukraine
  • Local Institution
    Odessa, 65009, Ukraine
  • Local Institution
    Odessa, 65039, Ukraine
  • Local Institution
    Odessa, 65114, Ukraine
  • Local Institution
    Vinnytsya, 21010, Ukraine
  • Local Institution
    Zhytomyr, 10003, Ukraine
09

References and documents

Publications

  • Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012 May;66(5):446-56. doi: 10.1111/j.1742-1241.2012.02911.x. Epub 2012 Mar 13. PubMed 22413962 ↗
  • Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19. PubMed 26894924 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 7 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Mar 26, 2008
Start
Jun 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Feb 23, 2017
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00643851
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 26, 2008
Start date
Jun 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Feb 23, 2017
Last update
Jan 30, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Metformin

Start the discussion